Abstracts tagged "arthritis management"

Abstract Number: 1139 • 2013 ACR/ARHP Annual Meeting
Pyogenic Arthritis: Clinical and Epidemiological Features Of 101 Cases At a University Hospital
Anne Riveros-Frutos¹, Lourdes Mateo¹, Melania Martínez-Morillo², Beatriz Tejera³, Samantha Rodriguez-Muguruza¹, Juana Sanint¹, Susana Holgado¹, Jerónima Cañellas¹, Xavier Tena¹, Alejandro Olivé¹ and Montserrat Gímenez⁴, ¹Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ²Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ³Rheumatology, University Hospital of Canary Islands, Santa Cruz de Tenerife, Spain, ⁴Microbiology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain
Background/Purpose: To describe the clinical characteristics, treatment and outcome of patients diagnosed with pyogenic septic arthritis. Methods: Design: retrospective (1984-2012). Location: University hospital. Referial area:…
Abstract Number: 834 • 2013 ACR/ARHP Annual Meeting
Physical Activity Behavior In Patients With Arthritis
Gustavo J. Almeida¹ and Sara R. Piva², ¹Department of Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ²Physical Therapy, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: : The physical activity (PA) guidelines issued by the US Health and Human Services (HHS) recommend that adults with arthritis should perform at least…
Abstract Number: 474 • 2013 ACR/ARHP Annual Meeting
HM-0523, a Novel Syk Inhibitor Significantly Ameliorates The Severity Of Arthritis In Rodents
Yu Cai¹, Zhong Cui Sun¹, Ping Ren¹, Lei Fang¹, Xiaoming Dai¹, Zhipeng Wu¹, Qianqian Dong², Xinrong Wang¹, Jian Wang¹, Yang Sai¹, Xiong Li¹ and Weiguo Su¹, ¹Hutchison Medipharma Limited, Shanghai, China, ²Inflammation & Immunology Research, Hutchison Medipharma Limited, Shanghai, China
Background/Purpose: Spleen tyrosine kinase (SYK) is a key mediator of signaling events downstream of a wide array of receptors important for immune function, including the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].